OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond dri

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developi

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

Zai Lab (NASDAQ: ZLAB - Get Free Report) and Viridian Therapeutics (NASDAQ: VRDN - Get Free Report)

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expa

Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen'

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Thera

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN)

Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ

U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutic

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Compa

OTTAWA, Ontario, June 05, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or t

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developi

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Co

Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a prim

OTTAWA, May 14, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Compan

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial

Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidanc

Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen I

Viridian shares fall after Amgen TEPEZZA Phase 3 data shows stronger efficacy, raising concerns over

Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW c

Viridian (VRDN) shares plunge 38% premarket despite positive Phase 3 TED trial data. Analysts weigh

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped highe

Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility rev

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  During Thursday's session, 406 companies made new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earn

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly

  Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings f

  On Friday, 1043 companies hit new 52-week lows.

Upgrades